drugset / Trial / NCT05395845

Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2

NCT05395845

Phase 0 Unknown 88 enrolled Aya abdelnasser hassani
NaSingle-groupOpen-labelTreatment

Summary

The study will be conducted to evaluate : The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.

Timeline

Start
2022-06-01
Primary completion
2022-12-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelets Rich Plasma Protein / enzyme biologic Other

Indications